Archived AES Symposia 2005
Professionals in Epilepsy Care Symposium - Controversies and Challenges of EEG Monitoring
Program Length: 2 hrs 9 min
This symposium will appeal to all care providers with an interest in electroencephalographic (EEG) monitoring in children and adults. Controversies and issues specific to EEG, such as the different types of electrodes, montages, placement of leads and various recording techniques will be presented. The challenges of obtaining optimal recordings in children and specific strategies for monitoring in children will be discussed. Intricacies of pharmacological methods in titration of antiepileptic drugs during EEG monitoring will be highlighted, as well as treatment of agitation and psychosis as they relate to seizure frequency. Coping with problems and remedial techniques for the patient and family will add to the interventional aspect of this symposium. Safety of staff, patients and families during non-invasive and invasive monitoring will conclude the presentations.
Join us during the symposia reception (6:00-7:00 p.m.) for a Practice Resources Show and Tell. Several of your colleagues have volunteered to display their best practice resources as models you may want to use.
At the conclusion of this activity, participants should be able to:
- Discuss the usefulness of EEG monitoring in the diagnosis and treatment of epilepsy
- Distinguish the differences in techniques used, between children and adults, for obtaining optimal EEG recordings
- Plan effective drug withdrawal for provocation of seizures prior to and titration upward of drug dosages following EEG monitoring
- Formulate pharmacological plans for treating the agitated patient in a monitoring unit
- Recognize ineffectual coping techniques and apply strategies for effective coping
- Implement safety procedures based upon current information from EEG monitoring units.
Nurses, physicians, EEG technologists, pharmacists, social workers and neuropsychologists.
Co-Chairs: Christine ODell, RN, M.S.N., CNS and Barry E. Gidal, Pharm.D.
This program and its repurposing on the AES Web site with CME credit is supported by an educational grant from UCB Pharma, Inc.
Disclosure: It is the policy of the American Epilepsy Society that all faculty participating in continuing medical education activities are expected to disclose to the program audience (1) any real or apparent conflict(s) of interest related to the content of their presentation and (2) discussions of unlabeled or unapproved uses of drugs or medical devices. The American Epilepsy Society adheres to the ACCMEs Essential Areas and Policies regarding industry support of continuing medical education. Disclosure by faculty of commercial relationships, if any, and discussions of unlabeled or unapproved uses will be made.
Mary A. Bare, RN, MSPH has indicated that she has received consulting fees from Eisai and Ortho-McNeil Pharmaceuticals. In addition, she has received fees for non-CME services from Cyberonics.
Lynn Bennett Blackburn, Ph.D.has indicated that she has no real or apparent conflicts to report.
Dennis J. Dlugos, M.D. has indicated that he has received consulting fees from Johnson & Johnson Pharmaceutical Research & Development and UCB Pharma. In addition, he has received fees for non-CME services from Ortho-McNeil Pharmaceuticals and Eisai.
Collin Hovinga, Pharm.D. has indicated that he has received consulting fees from Ortho-McNeil Pharmaceuticals. He has also performed contracted research for GlaxoSmithKline. In addition, he has received fees for non-CME services from GlaxoSmithKline and UCB Pharma.
Judy Ahn-Ewing, R.EEG/EPT has indicated that she has no real or apparent conflicts to report.
Disclaimer: Opinions expressed with regard to unapproved uses of products are solely those of the faculty and are not endorsed by the American Epilepsy Society or any manufacturers of pharmaceuticals.